Regentis Biomaterials Names Ori Gon Chief Financial Officer And Chief Business Officer, As GelrinC Progresses In US Food and Drug Administration Phase III Trial

GelrinC, the only restorative product for knee cartilage repair, has CE Mark approval in Europe and is currently at the midpoint of a pivotal FDA Phase III trial in the U.S.

Ori Gon brings substantial public company, medtech, and capital markets experience